Login to Your Account



Dynavax Signs $810M Deal with GSK in Lupus, Arthritis

By Donna Young


Thursday, December 18, 2008
Dynavax Technologies Corp. signed a deal with GlaxoSmithKline plc to develop endosomal toll-like receptor (TLR) inhibitors targeting immunoinflammatory diseases, which could potentially be worth more than $810 million for the Berkeley, Calif.-based biotech.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription